Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12764968 | 0.84 | GFER (0.49) | PARP1MAPTGFERKDM4EGAA | |
| SCHEMBL12764963 | 0.83 | GFER (0.47) | MAPTGFERKDM4EGAAHTT | |
| SCHEMBL12765010 | 0.76 | KDM4E (0.51) | PARP1KDM4EHSD17B10 | |
| SCHEMBL6624747 | 0.76 | GFER (0.70) | PARP1MAPTGFERKDM4EGAA | |
| SCHEMBL6683973 | 0.75 | GFER (0.68) | PARP1MAPTGFERKDM4EGAA | |
| SCHEMBL12764962 | 0.74 | PIM1 (0.44) | MAPTGFERKDM4EGAAHTT | |
| SCHEMBL12764966 | 0.74 | PIM1 (0.44) | MAPTGFERKDM4EGAAHTT | |
| SCHEMBL12764967 | 0.73 | PIM1 (0.44) | MAPTGFERKDM4EGAAHTT | |
| SCHEMBL12764964 | 0.73 | PIM1 (0.44) | MAPTGFERKDM4EGAAHTT | |
| SCHEMBL12764973 | 0.73 | PIM1 (0.44) | PARP1MAPTGFERKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071136-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071136-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071136-A1 | NOVEL TRICYCLIC PROTEIN KINASE MODULATORS | PACSIN2, CSNK2A3, CKS2 | PARP1 958/4885MAPT 2074/4885GFER 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.